1	TITLE: Prevalence and Outcomes Associated with Idarucizumab Administration in Trauma
2	Patients on Preinjury Dabigatran Therapy: Analyzing Clinical Utilization in 942 Patients from 74
3	Hospitals
4	
5	AUTHOR NAMES, ACADEMIC DEGREES, AND AFFILIATIONS:
6	Rebecca L. Moore, PharmD: HCA Healthcare/University of Tennessee College of Pharmacy
7	PGY2 Residency Program, Clinical Services Group, HCA Healthcare, Nashville, TN 37203 ;
8	rebecca.moore2@hcahealthcare.com
9	
10	Ransom J. Wyse, MPH: Center for Trauma and Acute Care Surgery Research, Clinical Services
11	Group, HCA Healthcare, Nashville, TN 37203 ; ransom.wyse@hcahealthcare.com ; ORCID #:
12	0000-0003-4558-1702
13	
14	Justin Jacobs, MS: Center for Trauma and Acute Care Surgery Research, Clinical Services
15	Group, HCA Healthcare, Nashville, TN 37203 ; justin.jacobs@hcahealthcare.com ; ORCID #:
16	0000-0002-5621-5962
17	
18	Samir M. Fakhry, MD: Center for Trauma and Acute Care Surgery Research, Clinical Services
19	Group, HCA Healthcare, Nashville, TN 37203 ; <u>Samir.fakhry@hcahealthcare.com</u> ; ORCID #:
20	0000-0002-6781-0863
21	

22	Nina Y. Wilson, MSN: Center for Trauma and Acute Care Surgery Research, Clinical Services
23	Group, HCA Healthcare, Nashville, TN 37203 ; <u>nina.yoes@hcahealthcare.com</u> ; ORCID #:
24	0000-0002-2560-7779
25	
26	Jeneva M. Garland, PharmD: Center for Trauma and Acute Care Surgery Research, Clinical
27	Services Group, HCA Healthcare, Nashville, TN 37203 ; jenny.garland@hcahealthcare.com ;
28	ORCID #: 0000-0003-4920-3020
29	
30	AUTHOR AFFILIATION: This research was supported (in whole or in part) by HCA
31	Healthcare and/or an HCA Healthcare affiliated entity. The views expressed in this publication
32	represent those of the authors and do not necessarily represent the official views of HCA
33	Healthcare or any of its affiliated entities.
34	
35	MEETING PRESENTATION: This work was presented as a poster presentation at the Annual
36	Midyear Clinical Meeting and Exhibition of the American Society of Health-System Pharmacists
37	in Las Vegas, Nevada, on December 7, 2022.
38	
39	SHORT TITLE: Idarucizumab Administration in Trauma Patients
40	
41	CORRESPONDING AUTHOR:
42	Samir M. Fakhry, MD FACS
43	Center for Trauma and Acute Care Surgery Research
44	HCA Healthcare, Clinical Services Group

- 45 2515 Park Plaza, Bldg 2-3W
- 46 Nashville, TN 37203
- 47 Mobile phone: 615-295-6844
- 48 Work phone: 615-344-5408
- 49 <u>samir.fakhry@hcahealthcare.com</u>
- 50
- 51 MANUSCRIPT WORD COUNT: 3,447
- 52 ABSTRACT WORD COUNT: 345
- 53

54 ICMJE AUTHORSHIP CONTRIBUTIONS:

55 RLM: Conceptualization, Methodology, Investigation, Writing - Original Draft, Writing -

56 Review & Editing, Supervision, Project Administration **RJW**: Methodology, Investigation,

57 Writing - Original Draft, Writing - Review & Editing, Project Administration JJ: Software,

58 Validation, Formal Analysis, Investigation, Data Curation, Writing - Original Draft, Writing -

59 Review & Editing, Visualization SMF: Conceptualization, Methodology, Investigation, Writing

60 - Review & Editing, Supervision, Visualization, Project Administration NYW: Methodology,

- 61 Investigation, Writing Review & Editing, Visualization JMG: Conceptualization,
- 62 Methodology, Investigation, Writing Original Draft, Writing Review & Editing, Supervision,
- 63 Project Administration

65 ABSTRACT

66	Background: Increasing numbers of injured patients taking dabigatran are presenting to trauma
67	centers raising an important clinical question: Does reversal with idarucizumab outweigh
68	potential bleeding risks associated with dabigatran? The purpose of this study was to describe the
69	prevalence of idarucizumab administration in trauma patients and compare outcomes for those
70	who received reversal to those who did not.
71	Methods : This retrospective cohort study included trauma inpatients ≥ 18 years on preinjury
72	dabigatran. Patients were sourced from the registries of Level I-IV trauma centers with an arrival
73	date 1/2017–12/2021. Preinjury dabigatran therapy and idarucizumab administration were
74	confirmed via EMR chart review. Patients on preinjury dabigatran were grouped according to
75	administration status of idarucizumab.
76	Results : 942 trauma patients on preinjury dabigatran (49.7% male; mean GCS:15; \geq 70 years:
70	Results : $y+z$ tradina patients on preinjury dabigatian (+ y . 170 mate, mean Geb.15, $z/0$ years.
77	85.7%) were included, with 10.8% patients reversed with idarucizumab. No statistically
77	85.7%) were included, with 10.8% patients reversed with idarucizumab. No statistically
77 78	85.7%) were included, with 10.8% patients reversed with idarucizumab. No statistically significant differences were found for preinjury dabigatran dose (p=0.703), age (p=0.494), blunt
77 78 79	85.7%) were included, with 10.8% patients reversed with idarucizumab. No statistically significant differences were found for preinjury dabigatran dose (p=0.703), age (p=0.494), blunt injury type (p=0.070), or mechanism of injury (p=0.248). Those reversed with idarucizumab had
77 78 79 80	85.7%) were included, with 10.8% patients reversed with idarucizumab. No statistically significant differences were found for preinjury dabigatran dose (p=0.703), age (p=0.494), blunt injury type (p=0.070), or mechanism of injury (p=0.248). Those reversed with idarucizumab had a greater median head AIS score (3 vs 2; p<0.001), higher proportion full trauma activations
77 78 79 80 81	85.7%) were included, with 10.8% patients reversed with idarucizumab. No statistically significant differences were found for preinjury dabigatran dose (p=0.703), age (p=0.494), blunt injury type (p=0.070), or mechanism of injury (p=0.248). Those reversed with idarucizumab had a greater median head AIS score (3 vs 2; p<0.001), higher proportion full trauma activations (16.7 vs 8.7%; p=0.019), higher median ISS (10 vs 9; p<0.001), were more likely to have a GCS
77 78 79 80 81 82	85.7%) were included, with 10.8% patients reversed with idarucizumab. No statistically significant differences were found for preinjury dabigatran dose (p=0.703), age (p=0.494), blunt injury type (p=0.070), or mechanism of injury (p=0.248). Those reversed with idarucizumab had a greater median head AIS score (3 vs 2; p<0.001), higher proportion full trauma activations (16.7 vs 8.7%; p=0.019), higher median ISS (10 vs 9; p<0.001), were more likely to have a GCS $3-8$ (4.9% vs 0.8%; p=0.006), and had increased rates of blood transfusion (4.9% vs 1.3%;

86	Conclusions: In this large, retrospective cohort study of trauma patients, only 10.8% had
87	reversal with idarucizumab. Patients reversed were more severely injured, with increased ICU
88	and ventilator use, more transfusions ≤ 24 hours, and had increased mortality compared to those
89	not reversed. There was no difference in thromboembolic events between groups. These findings
90	suggest clinicians may be administering idarucizumab based on injury severity – especially head
91	trauma – regardless of other variables, such as comorbidities. Additional research is needed to
92	determine the optimal role of reversal with idarucizumab vs. other strategies for injured patients
93	on dabigatran.
94	
95	KEYWORDS: Idarucizumab; Anticoagulant Reversal Agents; Dabigatran; Thromboembolism;

- 96 Bleeding
- 97

98 Clinical Perspective

99 What is new?

100	•	Trauma patients on preinjury dabigatran reversed with idarucizumab were more severely
101		injured and utilized more hospital resources (including increased intensive care unit
102		length of stay and ventilator days) than those not reversed.
103	•	There was no difference in thromboembolic events recorded between trauma patients
104		administered idarucizumab compared to those who were not; however, reversal with
105		idarucizumab was associated with increased rates of blood transfusion and total mortality
106		(expired + hospice).
107		
108	What	are the clinical implications?
109	•	These findings suggest clinicians may be administering idarucizumab to trauma patients
110		based primarily on injury severity, especially head trauma, regardless of other variables,
111		such as comorbidities.
112	•	A large, prospective randomized study of trauma inpatients on preinjury dabigatran that
113		compares dabigatran reversal with idarucizumab to non-specific reversal agents is
114		warranted to establish appropriate criteria for utilization of idarucizumab.
115		
116		

117 NON-STANDARD ABBREVIATIONS AND ACRONYMS:

- 118 DOAC: direct oral anticoagulants
- 119 FDA: Food and Drug Administration
- 120 DVT: deep vein thrombosis
- 121 PE: pulmonary embolism
- 122 TBI: traumatic brain injury
- 123 NSTEMI: non-ST elevation myocardial infarction
- 124 ED: emergency department
- 125 MOI: mechanism of injury
- 126 ICD-10-CM: International Classification of Diseases, Tenth Revision, Clinical Modification
- 127 EMR: electronic medical record
- 128 MAR: medication administration record
- 129 EDW: electronic data warehouse
- 130 ICU: intensive care unit
- 131 LOS: length of stay, reported in days
- 132 IRB: institutional review board
- 133 STROBE: Strengthening the Reporting of Observational Studies in Epidemiology
- 134 ISS: injury severity score
- 135 IQR: interquartile range
- 136 GCS: Glasgow Coma Score
- 137 AIS: abbreviated injury score
- 138

139 **INTRODUCTION**

Warfarin has long been considered the gold standard for anticoagulation for a wide range of 140 conditions. As evidence accumulates on the role of direct oral anticoagulants (DOAC) in the 141 142 prevention of thrombosis, more patients are transitioning from warfarin to DOAC therapy. From 2011 to 2017, prescriptions for DOACs as a proportion of all oral anti-coagulants increased from 143 22.1% to 87.3%, whereas warfarin prescriptions decreased from 77.9% to 12.7%.¹ As expected, 144 with the increase in DOAC prescriptions, there has been an increase in the prevalence of injured 145 patients arriving at hospitals who are on preinjury DOAC therapy, including dabigatran. 146 147 Dabigatran is a DOAC approved by the Food and Drug Administration (FDA) to reduce the risk 148 of stroke and systemic embolism in those with atrial fibrillation, to treat deep venous 149 150 thromboembolism (DVT) and pulmonary embolism (PE) in patients who have been on a 5-10151 day course of a parenteral anticoagulant, to reduce recurrence of DVT and PE, and for DVT and PE prophylaxis in patients who have recently experienced hip replacement surgery.² Dabigatran 152 153 is the third most frequently prescribed DOAC- with the majority of patients prescribed the drug being in the geriatric age group.³ 154

155

The proportion of individuals aged ≥65 years in the US is growing, having increased by onethird between 2010 and 2020,^{4,5} and making up 50.7% of all trauma admissions in 2016.⁶
Indications for dabigatran are more prevalent in the geriatric age group (e.g. atrial fibrillation),
and as the use of dabigatran and other DOACs has also increased, more trauma patients are
presenting on preinjury DOAC therapy. Furthermore, older individuals have an increased
tendency to fall, and anticoagulant therapy such as dabigatran, places them at an increased risk of

162	hemorrhage – even life-threatening bleeding – in situations such as traumatic brain injury
163	(TBI). ^{2,7} Growth in the geriatric population and increased prescribing of dabigatran places more
164	individuals at risk for bleeding complications from trauma, and underscores the importance of
165	clinical-decision making in the evaluation and management of a trauma patient on preinjury
166	dabigatran, balancing the risks of bleeding against those of thrombo-embolic events.
167	
168	Idarucizumab is a human monoclonal antibody fragment approved by the FDA for the reversal of
169	dabigatran, specifically binding to the DOAC to neutralize its anticoagulant effect. Importantly,
170	idarucizumab is FDA approved for use in emergency surgeries or urgent procedures and life-
171	threatening or uncontrolled bleeding. ⁸ Regardless of these approved indications, the
172	administration of idarucizumab is widely disputed among emergency clinicians due to potential
173	adverse events, cost, and lack of supporting literature concerning its use in trauma patients. ^{9,10}
174	Post-marketing and case reports have indicated idarucizumab administration to potentially be
175	associated with an increased thromboembolic risk, including DVT, PE, atrial thrombus, non-ST
176	elevation myocardial infarction (NSTEMI), and ischemic stroke. ¹¹ Despite reports of these
177	events occurring in less than 1% of patients, ¹¹ these thromboembolic adverse reactions prompt
178	concern. As trauma patients are inherently in a hypercoagulable state, ¹² clinicians are faced with
179	the decision as to whether reversal with idarucizumab in this patient population outweighs the
180	potential bleeding risks associated with dabigatran.
181	
182	The purpose of this retrospective cohort study was to describe the prevalence of idarucizumab

administration in a large sample of trauma patients from a single, nationwide hospital system and

- 184 compare the outcomes of trauma inpatients on preinjury dabigatran who received reversal with
- 185 idarucizumab to those who did not receive idarucizumab.
- 186

187 METHODS

188 Study sample and data sources

In this retrospective cohort study, trauma patients from a large hospital network were included if 189 190 they were ≥ 18 years, on pre-injury dabigatran therapy, and presented to the emergency department (ED) between January 1, 2017 and December 31, 2021. Patient demographics 191 192 including age, sex, race, and injury characteristics (injury type and mechanism) were retrieved from the system-wide trauma registry. Mechanism of injury (MOI) for each patient was 193 identified using International Classification of Diseases, Tenth Revision, Clinical Modification 194 195 (ICD-10-CM) external cause of injury codes. Preinjury dabigatran use was retrieved from the 196 electronic medical record (EMR), which included patient-reported documentation of home 197 medications in patients' medical history, while idarucizumab dose and administration were 198 sourced from the ED medication administration record (MAR). Preinjury dabigatran therapy and idarucizumab administration were further confirmed via EMR data from the electronic data 199 warehouse (EDW). Each patient record was assessed for dabigatran therapy and idarucizumab 200 administration, identified by both the generic and trade names (Pradaxa[®] and Praxbind[®]. 201 respectively) via string search. Only patients taking a preinjury dose of dabigatran 75 mg twice 202 daily or 150 mg twice daily were included; patients who reported preinjury dabigatran 110 mg or 203 dabigatran 220 mg were excluded, as this dose is currently only indicated for prophylaxis of 204 DVT and PE following hip replacement surgery.² Patients with nontraumatic ischemic or 205 206 hemorrhagic strokes that were present on admission were excluded.

207

208 Variable definitions

The primary goal of the study was to characterize the administration of the reversal agent 209 210 idarucizumab among trauma patients on preinjury dabigatran therapy. Patients on preinjury dabigatran were grouped according to whether or not they were administered the dabigatran 211 212 reversal agent, idarucizumab. Administration of idarucizumab – including dosage and time of 213 dose – was sourced from drug administration data in the EDW using string search on the generic name and trade name of Praxbind[®]. Any inconsistencies in the documentation of idarucizumab 214 215 administration were reviewed by a clinical staff pharmacist on the study team to confirm dosing 216 records for accuracy.

217

218 Secondary outcomes included patient-related outcomes for trauma patients on preinjury 219 dabigatran who were administered idarucizumab compared to those who were not administered 220 idarucizumab. These patient outcomes included hemorrhagic events, thromboembolic events, 221 discharge disposition, total mortality, and hospital resource utilization. Hemorrhagic events included hemorrhagic stroke or "bleeding"; since this outcome was not consistently captured in 222 the EDW, "bleeding" was defined as the occurrence of a blood transfusion within the first 0-4223 224 hours or 5-24 hours of admission as a proxy variable, given this temporal parameter was consistently documented in the trauma registry. Thromboembolic events included 225 226 thromboembolic stroke, DVT, or PE. Both hemorrhagic stroke and thromboembolic stroke 227 events were sourced from the EDW using ICD-10-CM diagnosis codes (Supplemental Table 1). "Total mortality" was defined as the proportion of patients who expired as an inpatient, or were 228 229 discharged to hospice. Therefore, "Total mortality" was the sum of inpatient deaths ("Expired")

and hospice discharges ("Hospice") as documented in the trauma registry.¹³ Hospital resource
utilization information was also extracted from the trauma registry, and included length of stay
(LOS, reported in days), intensive care unit (ICU) utilization, ICU LOS, ventilator utilization,
and days on a ventilator.

234

The R package 'comorbidity' was used to compute a van Walraven weighted Elixhauser score.¹⁴ Since the specific indication for preinjury dabigatran therapy was not consistently available in the EDW or trauma registry, the EDW was searched for the presence of the comorbidity of interest for which dabigatran therapy is indicated, i.e. atrial fibrillation. History of atrial fibrillation, or the presence of atrial fibrillation on arrival using ICD-10-CM diagnosis codes, was deemed the most likely primary reason for dabigatran therapy (Supplemental Table 1).

241

242 Statistical analyses

Descriptive analyses comparing trauma patients who were administered idarucizumab to those 243 244 who did not receive idarucizumab were performed for patient demographics, diagnoses, and outcomes using Pearson χ^2 tests of association for categorical variables, and Wilcoxon Rank Sum 245 tests for continuous variables. Fisher's exact test was used for categorical outcomes with fewer 246 247 than ten results in each category. P values less than .05 were considered statistically significant. R software version 4.2.2 was used for all analyses.¹⁵ The Institutional Review Board (IRB) of the 248 University of Tennessee Health Science Center waived ethical approval for this work and 249 250 determined it to be exempt from IRB oversight. The Strengthening the Reporting of 251 Observational Studies in Epidemiology (STROBE) guidelines were utilized in the reporting of

252	this research (Supplemental Table 2). ¹⁶ The authors had full access to all data in the study and
253	take responsibility for the integrity of the data and accuracy of the data analysis.

254

255 **RESULTS**

256 **Patient characteristics**

257 There were 500 339 patients in the trauma registry that presented to one of 74 facilities, which

included 8 Level I, 35 Level II, 20 Level III, and 11 Level IV trauma centers, between January 1,

259 2017, and December 31, 2021. Only 1177 (0.2%) met the aforementioned study criteria for

260 preinjury dabigatran use. Fifty-two patients admitted to facilities that did not have idarucizumab

on formulary during the study period were excluded from the analysis. In addition, admissions

that did not meet the inclusion criteria were withdrawn (duplicate trauma identifications = 7;

under age 18 = 1; patients on hip replacement 110 mg dabigatran dose = 41; nontraumatic stroke

present on arrival = 134). After these exclusions, 942 unique patients remained, with 102

(10.8%) who received idarucizumab and 840 (89.2%) who did not (Figure 1).

266

The majority of patients were 70 years of age or older (85.7%), with 484 (51.4%) in the 70 – 84 267 age range. There were 474(50.3%) female patients. The study sample was predominantly White 268 269 (92.9%), with 18 (1.9%) Black patients and 49 (5.2%) Other races. A higher proportion of Black 270 patients were administered idarucizumab compared to those who did not receive idarucizumab 271 (4.9% vs 1.5%, P=0.037). Ninety-one patients received the FDA recommended dosage of 5 272 grams (89.2%), 5 patients received 2.5 grams (4.9%), 2 patients received 10 grams (2.0%), and there was missing dosage administration data for 4 patients (3.9%). There were 795 (84.4%) 273 274 patients with a documented history of atrial fibrillation, which was identified as a proxy of the indication for their preinjury dabigatran therapy. A statistically significantly larger proportion of 275

- 276 patients administered idarucizumab had a full trauma activation on arrival compared to patients
- who did not receive the reversal drug (16.7% vs 8.7%, *P*=0.019; Table 1). No statistically
- significant differences were found for sex, age, Elixhauser score, transfers in, indication for
- 279 dabigatran therapy, or dabigatran dose between patients who were administered idarucizumab
- and those who were not (Table 1).
- 281 **Table 1.** Demographic and Clinical Patient Characteristics

	Overall	Idarucizumab Grouping		
Patient Demographics		Idarucizumab	No	P
i attent Demographies			Idarucizumab	value
	N=942	n=102 (10.8%)	n=840 (89.2%)	
Female sex, n (%)	474 (50.3%)	47 (46.1%)	427 (50.8%)	.364
Race				.048
White, n (%)	875 (92.9%)	90 (88.2%)	785 (93.5%)	.065
Black, n (%)	18 (1.9%)	5 (4.9%)	13 (1.5%)	.037
Other, n (%)	49 (5.2%)	7 (6.9%)	42 (5.0%)	.475
Age, y, median [IQR] [†]	81 [74, 87]	80 [74.3, 86.5]	81 [74, 87]	.650
Age group				.494
18-54 years, n (%)	19 (2.0%)	1 (1.0%)	18 (2.1%)	.711
55-69 years, n (%)	116 (12.3%)	11 (10.8%)	105 (12.5%)	.750
70-84 years, n (%)	484 (51.4%)	60 (58.8%)	424 (50.5%)	.117
≥85 years, n (%)	323 (34.3%)	30 (29.4%)	293 (34.9%)	.320
Elixhauser score, median [IQR] [†]	10 [5, 17]	9 [5, 16.8]	11 [5, 17]	.264
Transfers in, n (%)	186 (19.7%)	20 (19.6%)	166 (19.6%)	.971
Activation type				.010
Full, n (%)	90 (9.6%)	17 (16.7%)	73 (8.7%)	.019
Partial, n (%)	266 (28.2%)	31 (30.4%)	235 (28.0%)	.642
Consult, n (%)	255 (27.1%)	30 (29.4%)	225 (26.8%)	.557
None, n (%)	266 (28.2%)	15 (14.7%)	251 (29.9%)	.001
Unknown/Missing, n (%)	65 (6.9%)	9 (8.8%)	56 (6.7%)	.408
Preinjury dabigatran indication				.791
Atrial fibrillation, n (%)	795 (84.4%)	87 (85.3%)	708 (84.3%)	-
Other, n (%)	147 (15.6%)	15 (14.7%)	132 (15.7%)	-
Preinjury dabigatran dose			.703	
75 mg BID [†] , n (%)	262 (27.8%)	30 (29.4%)	232 (27.6%)	-
150 mg BID [†] , n (%)	680 (72.2%)	72 (70.6%)	608 (72.4%)	-

*All comparisons between idarucizumab administration and no idarucizumab administration were

significant at P < .05.

284 [†]Abbreviations: IQR=interquartile range; BID=bis in die (twice a day).

286 Injury description

287	Falls were the most common MOI (85.2%), with 639 (67.8%) patients presenting for same-level
288	falls, and 164 (17.4%) categorized in the trauma registry as "other falls" (Table 2). The MOI was
289	not statistically significantly different between those who received idarucizumab and those who
290	did not (P=0.248). Overall, median injury severity score (ISS) was 9 [interquartile range (IQR)
291	4-10], but the group administered idarucizumab had a statistically significantly higher median
292	score than those who did not (10 [IQR $8 - 17$] vs 9 [IQR $4 - 9$]; P<0.001). Similarly, when ISS
293	was categorized, there was a greater proportion of patients in the more severely injured " $16 - 24$ "
294	and "25" ISS groupings for those who were administered idarucizumab compared to patients
295	who did not receive the drug (29.4% vs 3.8%, and 10.8% vs 2.1%, respectively; P <0.001).
296	Median Glasgow Coma Score (GCS) was 15 [IQR 15 – 15] across the sample, as well as in each
297	group; however, when GCS was examined by category, the idarucizumab group had a
298	statistically significantly higher proportion of patients in the most severe " $3 - 8$ " range, with 5
299	(4.9%) patients compared to 7 (0.8%) patients who did not receive idarucizumab (P <0.001).
300	Furthermore, patients administered idarucizumab were more likely to have a higher head
301	abbreviated injury score (AIS), with the median being 3 [IQR $3 - 4$], compared to those who
302	were not administered idarucizumab (2 [IQR $2 - 3$]). All injury characteristics are reported in
303	Table 2.
304	
305	
306	
307	

308

309 Table 2. Injury Patterns of Patients Administered Idarucizumab Compared to Patients Who Did

310 Not Receive Idarucizumab

	0	Idarucizumab Grouping		Р	
	Overall	Idarucizumab	No Idarucizumab	*	
	N=942	n=102 (10.8%)	n=840 (89.2%)	value	
Injury type			-	.070	
Blunt, n (%)	924 (98.1%)	98 (96.1%)	826 (98.3%)	.121	
Penetrating, n (%)	8 (0.8%)	3 (2.9%)	5 (0.6%)	.046	
Other/unspecified, n (%)	3 (0.3%)	0 (0.0%)	3 (0.4%)	1.000	
Missing injury type, n (%)	7 (0.7%)	1 (1.0%)	6 (0.7%)	.553	
MOI				.248	
Same level fall, n (%)	639 (67.8%)	63 (61.8%)	576 (68.6%)	.178	
Other fall, n (%)	164 (17.4%)	21 (20.6%)	143 (17.0%)	.406	
MVC, n (%)	59 (6.3%)	6 (5.9%)	53 (6.3%)	1.000	
Motorcycle, n (%)	9 (1%)	1 (1%)	8 (1%)	1.000	
Pedestrian, n (%)	12 (1.3%)	3 (2.9%)	9 (1.1%)	.132	
Pedal cyclist, n (%)	10 (1.1%)	2 (2.0%)	8 (1.0%)	.296	
Assault, n (%)	7 (0.7%)	2 (2.0%)	5 (0.6%)	.170	
Other, n (%)	39 (4.1%)	4 (3.9%)	35 (4.2%)	1.000	
Missing MOI, n (%)	3 (0.3%)	0 (0.0%)	3 (0.4%)	1.000	
ISS, median [IQR] [†]	9 [4, 10]	10 [8, 17]	9[4, 9]	<.001	
ISS 1 – 8, n (%)	426 (45.2%)	27 (26.5%)	399 (47.5%)	<.001	
ISS 9–15, n (%)	422 (44.8%)	33 (32.4%)	389 (46.3%)	.008	
ISS 16 – 24, n (%)	62 (6.6%)	30 (29.4%)	32 (3.8%)	<.001	
ISS ≥25, n (%)	29 (3.1%)	11 (10.8%)	18 (2.1%)	<.001	
Missing, n (%)	3 (0.3%)	1 (1.0%)	2 (0.2%)	.291	
AIS		T	1		
Head, median [IQR] [†]	3 [2, 3]	3 [3, 4]	2 [2, 3]	<.001	
Face, median [IQR] [†]	3 [2, 3]	2.5 [2, 3]	3 [2, 3]	.639	
Chest, median [IQR] [†]	2 [1, 2]	2 [1, 2]	2 [1, 2]	.879	
Abdomen, median [IQR] [†]	3 [2, 3]	3 [2, 3]	3 [2, 3]	.613	
Extremities, median [IQR] [†]	2 [2, 2]	2 [2, 2]	2 [2, 2]	.790	
External, median [IQR] [†]	1 [1, 1]	1 [1, 1]	1 [1, 1]	.268	
GCS, median [IQR] [†]	15 [15, 15]	15 [15, 15]	15 [15, 15]	<.001	
GCS 3 – 8, n (%)	12 (1.3%)	5 (4.9%)	7 (0.8%)	.006	
GCS 9 – 12, n (%)	16 (1.7%)	4 (3.9%)	12 (1.4%)	.085	
GCS 13 – 15, n (%)	859 (91.2%)	91 (89.2%)	768 (91.4%)	.459	
Missing GCS, n (%)	55 (5.8%)	2 (2.0%)	53 (6.3%)	.113	

*All comparisons between idarucizumab administration and no idarucizumab administration were

312 significant at P < .05.

313 *†*Abbreviations: MOI=Mechanism of Injury; MVC=motor vehicle collision; ISS=injury severity score;

314 IQR=interquartile range; AIS=Abbreviated injury score; GCS=Glasgow Coma Score.

316 Outcomes

- In the overall sample, there were 16(1.7%) patients who received transfusions, indicating
- significant hemorrhage. Patients administered idarucizumab were more likely to experience
- bleeding that required transfusion compared to those who did not receive idarucizumab (4.9% vs
- 320 1.3%, respectively; *P*=0.022; Table 3).

Table 3. Outcomes of Patients Administered Idarucizumab Compared to Patients Who Did Not

322 Receive Idarucizumab

		Idarucizum	ab Grouping	
	Overall	Idarucizumab	No	Р
		Idarucizuinad	Idarucizumab	value*
	N=942	n=102 (10.8%)	n=840 (89.2%)	
Hemorrhagic event, n (%)	16 (1.7%)	5 (4.9%)	11 (1.3%)	.022
Hemorrhagic stroke, n (%)	0	0	0	—
Transfusion within 24 hours, n (%)	16 (1.7%)	5 (4.9%)	11 (1.3%)	.022
0 - 4 hours, n (%)	16 (1.7%)	5 (4.9%)	11 (1.3%)	.022
5 – 24 hours, n (%)	4 (0.4%)	2 (2.0%)	2 (0.2%)	.006
Thromboembolic event, n (%)	7 (0.7%)	1 (1.0%)	6 (0.7%)	.553
Thromboembolic stroke, n (%)	4 (0.4%)	1 (1.0%)	3 (0.4%)	.368
Deep Vein thrombosis, n (%)	3 (0.3%)	0	3 (0.4%)	1.000
Pulmonary embolism, n (%)	1 (0.1%)	0	1 (0.1%)	1.000
ICU use, n (%)	315 (33.4%)	78 (76.5%)	237 (28.2%)	<.001
ICU LOS, days, median [IQR] [†]	3 [2,5]	3 [2, 5]	3 [2, 5]	.714
Ventilator use, n (%)	52 (5.5%)	11 (10.8%)	41 (4.9%)	.021
Ventilator days, median [IQR] [†]	3 [2, 7]	4 [2, 10]	3 [2, 6]	.352
Hospital LOS, days, median [IQR] [†]	4 [2, 6]	3 [2, 5]	4 [2, 6]	.147
Withdrawal of care	13 (1.4%)	4 (3.9%)	9 (1.1%)	.043
Discharge disposition				<.001
Expired, n (%)	30 (3.2%)	5 (4.9%)	25 (3.0%)	.362
Hospice, n (%)	20 (2.1%)	6 (5.9%)	14 (1.7%)	.015
Home, n (%)	346 (36.7%)	42 (41.2%)	304 (36.2%)	.329
Nursing facility, n (%)	332 (35.2%)	24 (23.5%)	308 (36.7%)	.009
Other, n (%)	214 (22.7%)	25 (24.5%)	189 (22.5%)	.619
Total Mortality (Expired +	50 (5.3%)	11 (10.8%)	39 (4.6%)	.017
Hospice), n (%)				

*All comparisons between idarucizumab administration and no idarucizumab administration were

324 significant at P < .05.

³²⁵ *†*Abbreviations: ICU=intensive care unit; LOS=length of stay; IQR=interquartile range.

327	A total of 7 (0.7%) patients had a thromboembolic event reported. There were 4 (0.4%) patients
328	who had a thromboembolic stroke, 3 (0.3%) who had a clinically detectable DVT, and 1 (0.1%)
329	who had a PE. The four patients who had either a clinically detectable DVT or PE were in the
330	group that did not receive idarucizumab, but there was no statistically significant difference
331	between the two groups for thromboembolic events of any kind (Table 3).
332	
333	In terms of hospital resource utilization, 76.5% of those administered idarucizumab had any LOS
334	in the ICU, while 28.2% of those not administered idarucizumab had any LOS in the ICU
335	(P <0.001). Despite this difference, patients had a similar median ICU LOS of 3 [IQR 2 – 5] days
336	both across the sample and within groups. Ventilator use was also more prevalent in those
337	administered idarucizumab (11 patients, 10.8%), compared to 41 (4.9%) patients for those who
338	did not receive idarucizumab ($P < 0.021$), though the number of days on a ventilator was not
339	statistically significantly different between the two groups, with an overall median of 3 [IQR $2-$
340	7] days.
341	
342	The total mortality, which was defined as the sum of patients who expired in the inpatient setting

and those who were discharged to hospice, was found to be statistically significantly different between the two groups, with a higher proportion among those administered idarucizumab compared to those who were not given the drug (10.8% vs 4.6%, P=0.017). This statistically significant difference in the proportion of total mortality was most affected by those discharged to hospice. In patients who received idarucizumab, 5.9% were discharged to hospice, while 1.7% were discharged to hospice in the patient group who did not receive idarucizumab (P=0.015). The number of patients who expired in the inpatient setting was not statistically significantly

350	different between the groups, 5 (4.9%) in the patient group who received idarucizumab
351	compared to 25 (3.0%) in patients who did not receive idarucizumab (P =0.362; Table 3).
352	

353 **DISCUSSION**

This retrospective cohort study was conducted to characterize the prevalence of idarucizumab 354 administration in trauma patients on preinjury dabigatran therapy. In the analysis of 942 trauma 355 356 patients on preinjury dabigatran therapy (0.2% of all trauma patients seen) from 74 level I-IV 357 trauma centers and non-trauma centers, 102 (10.8%) were administered idarucizumab for the 358 reversal of dabigatran. Patients who were administered idarucizumab were found to be more severely injured with a higher ISS and had an increased proportion of total mortality. Compared 359 to those who did not receive the reversal drug, idarucizumab administration was associated with 360 361 a higher proportion of full trauma activations, increased ICU and ventilator use, and more transfusions within the first 24 hours of admission. There was not a statistically significant 362 363 difference between the two groups for the number of individuals who expired in the hospital, but 364 patients who received idarucizumab were more likely to be discharged to hospice, which increased total mortality (expired in-hospital + hospice) in the group that received dabigatran 365 reversal with idarucizumab. There were no statistically significant differences in clinically 366 detectable thromboembolic events – including thromboembolic stroke, DVT, and PE – between 367 those who were administered idarucizumab and those who were not. 368

369

As the numbers of elderly patients continues to increase, comorbidities associated with aging –
such as atrial fibrillation¹⁷ – are also on the rise and frequently necessitate the use of
anticoagulant medications, including dabigatran.¹⁷⁻¹⁹ Despite the protective anticoagulative

373 properties dabigatran has to offer patients with atrial fibrillation, its use may pose increased 374 bleeding risks following injury. When emergency surgery or urgent procedures are needed, or a patient presents with life-threatening or uncontrolled bleeding, the reversal of dabigatran may be 375 376 required. Idarucizumab binds to dabigatran with 350 times greater affinity than does thrombin, thereby negating its anticoagulant effect, which is concerning, as studies have shown increased 377 adverse events in elderly patients when dabigatran is reversed with idarucizumab.^{20,21} Similar to 378 379 other studies regarding the use of idarucizumab in the reversal of dabigatran, the majority of patients who met eligibility criteria in this study were elderly.²²⁻²⁴ Despite the majority of 380 dabigatran reversal with idarucizumab tending to occur in the elderly, this study found there was 381 no association between increasing age and idarucizumab administration among trauma patients. 382 383 384 Several studies have reported the safety of idarucizumab administration. A retrospective casecontrol study that included hospitalized patients for dabigatran-associated nontraumatic 385 386 gastrointestinal bleeding or intracranial bleeding by Singh et al noted there were no significant 387 differences in mortality (odds ratio, 1.39 [95% CI, 0.51–3.45]) or venous thromboembolism (odds ratio, 0.35 [95% CI, 0.08–1.58]) for those who received idarucizumab compared to those 388 who did not receive the reversal drug.²⁵ Similarly, a meta-analysis by Chaudhary et al stated 389 390 idarucizumab had a "promising safety profile" with 82% anticoagulation reversal and low mortality (11%) and thromboembolic events (5%).²⁴ Chaudhary et al also instill a hint of doubt 391 by stating, "While the safety data from these landmark trials were promising, head-to-head trials 392 have not compared the safety and outcomes of idarucizumab or and exanet alfa (AA) with 393 traditional nonspecific reversal agents (FFP, 4F-PCC, or A-PCC)."²⁴ Furthermore, the 394 American College of Gastroenterology-Canadian Association of Gastroenterology Clinical 395

- Guideline recommends against the use of idarucizumab for those with gastrointestinal bleeding
 due to limited evidence of benefit and the high cost of the drug.²⁶
- 398

399 In this study, a statistically and clinically significant proportion of patients who received idarucizumab were more likely to be severely injured and have a full trauma activation, 400 compared to those who did not. Patients administered idarucizumab were more likely to have a 401 402 higher ISS, a higher rate of transfusion, a higher AIS of the head, a lower GCS, and increased 403 ICU and ventilator use. Consistent with these markers of severity and increased risk, they were 404 also more likely to have higher total mortality (expired in hospital + hospice). This statistically significant increased mortality for those who received idarucizumab is more likely related to the 405 patient's injury severity than to the administration of idarucizumab. Interestingly, compared to 406 407 those who did not receive idarucizumab, patients who were administered the drug were less likely to expire in the hospital, yet the total mortality calculation (expired in hospital+ hospice) 408 409 indicated a statistically significant increase in total mortality for those administered 410 idarucizumab, suggesting discharge to hospice – and not age itself as reported above – may play a role in this outcome as reported in previous studies of trauma patients.^{27,13} 411 412

Regardless of any hesitancy to utilize the drug, adherence to the idarucizumab FDA
recommended dosing appears to be relatively high. There are few large studies concerning
idarucizumab dosage compliance. Our study – with 89.2% compliance – was similar to a small
study by Mitrovic, et al. that included 68 patients on pre-admission dabigatran.²² They reported
94% of patients were administered idarucizumab with the appropriate FDA dosing guidance.

419	Idarucizumab administration may place trauma patients at an increased risk of thromboembolic
420	events, not only due to the coagulative drug properties of idarucizumab binding to dabigatran
421	and negating its anticoagulative effects, but also due to the fact that trauma patients present in a
422	hypercoagulable state. ²⁸ This study found no statistically significant differences in clinically
423	detectable thromboembolic events between groups. All patients were not actively surveilled for
424	this outcome or evaluated for these potential adverse events following discharge, limiting the
425	conclusion that may be drawn from this finding.
426	

The clinically important findings reported in this study may be indicative of specific effects of idarucizumab in the trauma patient, as few studies have been conducted strictly in this high-risk population. A small study of 15 trauma patients by Oberladstätter et al found similar results to this study, in which no patients who received idarucizumab experienced clinically detectable thromboembolic events. Conversely, previous studies that included non-trauma patients found idarucizumab administration to be associated with increased clinically detectable thromboembolic events.^{20,29}

434

435 Limitations

The usual cautions regarding retrospective analysis of administrative datasets are warranted, including the relatively small sample size. Due to the nature of patient-reported preinjury dabigatran use, there is the potential for cognitive bias. Therefore, we could not verify the time of the patients' last dose of dabigatran with certainty. Our dataset was also lacking detailed information concerning the indication for idarucizumab administration, as well as outcomes associated with each idarucizumab dose (eg, the cause of death or whether there was any

expansion of intracranial hemorrhages present on admission). Furthermore, initial dabigatran
serum concentration values and dabigatran serum concentration values following administration
of idarucizumab were not available.

445

446 Conclusions

This retrospective cohort study in trauma patients found 983 patients (0.2%) from 87 level I–IV 447 448 trauma centers were on preinjury dabigatran therapy and 102 (10.4%) were reversed with 449 idarucizumab. Patients administered idarucizumab were found to be more severely injured, and had increased ICU and ventilator use, more transfusions within the first 24 hours of admission, 450 and an increased total mortality compared to those who did not receive idarucizumab. There was 451 no statistically significant difference in clinically detectable thromboembolic events between the 452 453 two groups. These findings suggest clinicians may be administering idarucizumab based 454 primarily on injury severity, especially head trauma, regardless of other variables such as 455 comorbidities. There may be other more clinically appropriate dabigatran reversal agents in 456 trauma, which warrants further investigation. Additional research is needed to determine the optimal role of reversal with idarucizumab vs. other strategies for injured patients on dabigatran. 457 458

459 ACKNOWLEDGMENTS, SOURCES OF FUNDING, & DISCLOSURES

- 460 Acknowledgments: None
- 461 **Sources of Funding:** None
- 462 **Disclosures:** None

463

464

465 SUPPLEMENTAL MATERIAL

466 Tables S1-S2

467

469 **REFERENCES**

470	1.	Perreault S, de Denus S, White-Guay B, Côté R, Schnitzer ME, Dubé MP, Dorais M,
471		Tardif JC. Oral anticoagulant prescription trends, profile use, and determinants of
472		adherence in patients with atrial fibrillation. <i>Pharmacotherapy</i> . 2020;40(1): 40-54.
473	2.	Pradaxa. Package insert. Boehringer Ingelheim Pharmaceuticals, Inc; 2023.
474	3.	Simon TG, Schneeweiss S, Singer DE, Sreedhara SK, Lin KJ. Prescribing trends of oral
475		anticoagulants in US patients with cirrhosis and nonvalvular atrial fibrillation. J Am
476		Heart Assoc. 2023;12(3):e026863.
477	4.	United States Census Bureau. 65 and older population grows rapidly as baby boomers
478		age. Published June 25, 2020. Accessed December 6, 2023.
479		https://www.census.gov/newsroom/press-releases/2020/65-older-population-grows.html
480	5.	Vespa J. The U.S. joins other countries with large aging populations. United States
481		Census Bureau. Updated October 8, 2019. Accessed December 4, 2023.
482		https://www.census.gov/library/stories/2018/03/graying-america.html
483	6.	Rios-Diaz AJ, Metcalfe D, Olufajo OA, Zogg CK, Yorkgitis B, Singh M, Haider AH,
484		Salim A. Geographic distribution of trauma burden, mortality, and services in the in the
485		United States: does availability correspond to patient need?. J Am Coll Surg.
486		2016;223(6):764-773.e2.
487	7.	Scotti P, Séguin C, Lo BWY, de Guise E, Troquet JM, Marcoux J. Antithrombotic agents
488		and traumatic brain injury in the elderly population: hemorrhage patterns and outcomes. J
489		Neurosurg. 2019;133(2):1-10.
490	8.	Praxbind. Package insert. Boehringer Ingelheim Pharmaceuticals, Inc.; 2015.
491		

492	9. Selby R, Geerts W, Ofosu FA, Craven S, Dewar L, Phillips A, Szalai JP.
493	Hypercoagulability after trauma: hemostatic changes and relationship to venous
494	thromboembolism. Thromb Res. 2009;124(3):281-287.
495	10. Cuker A, Burnett A, Triller D, Crowther M, Ansell J, Van Cott EM, Wirth D, Kaatz
496	S. Reversal of direct oral anticoagulants: guidance from the Anticoagulation Forum. Am J
497	Hematol. 2019;94(6):697-709.
498	11. Idarucizumab. Lexi-Drugs. Lexicomp. UpToDate, Inc.; 2023. Updated May 11, 2023.
499	Accessed May 25, 2023. https://online.lexi.com
500	12. Moore EE, Moore HB, Kornblith LZ, Neal MD, Hoffman M, Mutch NJ, Schochl H, Hunt
501	BJ, Sauaia A. Trauma-induced coagulopathy. Nat Rev Dis Primers. 2021;7(1):30.
502	13. Fakhry SM, Shen Y, Wyse RJ, Garland JM, Watts DD. Variation in hospice use among
503	trauma centers may impact analysis of geriatric trauma outcomes: an analysis of
504	1,961,228 Centers for Medicare and Medicaid Services hospitalizations from 2,317
505	facilities. J Trauma Acute Care Surg. 2023;94(4):554-561.
506	14. van Walraven C, Austin PC, Jennings A, Quan H, Forster AJ. A modification of the
507	Elixhauser comorbidity measures into a point system for hospital death using
508	administrative data. Med Care. 2009;47(6):626-633.
509	15. R: A language and environment for statistical computing. R foundation for statistical
510	computing program. Vienna, Austria: R Core Team, 2021. https://www.R-project.org/.
511	Accessed August 27, 2023.
512	16. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, and
513	STROBE Initiative. The Strengthening the Reporting of Observational Studies in

514	Epidemiology	(STROBE)	statement:	guidelines	for repo	rting of	observational	studies.

- 515 *Epidemiology*. 2007;18(6):800-804.
- 516 17. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE, GO AS,
- 517 Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults:
- 518 national implications for rhythm management and stroke prevention: the
- 519 AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study.
- 520 *JAMA*. 2001;285(18):2370-2375.
- 521 18. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, Seward JB,
- 522 Tsang TSM. Secular trends in incidence of atrial fibrillation in Olmsted County,
- 523 Minnesota, 1980 to 2000, and implications on the projections for future prevalence.
- 524 *Circulation*. 2006;114(2):119-125.
- 525 19. Barnes GD, Lucas E, Alexander GC, Goldberger ZD. National trends in ambulatory oral
 526 anticoagulant use. *Am J Med*. 2015;128(12):1300-5.e2.
- 527 20. van der Wall SJ, van Rein N, van den Bemt B, Kruip MJHA, Meijer K, Te Boome LCJ,
- 528 Simmers TA, Alings AMW, Tieleman R, Klok FA, et al. Performance of idarucizumab as

antidote of dabigatran in daily clinical practice. *Europace*. 2019;21(3):414-420.

- 530 21. Rodrigues AO, David C, Ferreira JJ, Pinto FJ, Costa J, Caldeira D. The incidence of
- 531 thrombotic events with idarucizumab and and exanet alfa: a systematic review and meta-
- analysis. *Thromb Res*. 2020;196:291-296.
- 533 22. Mitrovic D, van Elp M, Visser L, van Rein N, van den Bemt P, van Hulst M, Dreijer A,
- Lameijer H, Veeger N, Meijer K, et al. Adherence to protocols for the use of reversal
- agents in patients treated with direct oral anticoagulants. *Curr Med Res*
- 536 *Opin*. 2023;39(6):865-871.

537	23. da Luz LT, Marchand M, Nascimento B, Tien H, Nathens A, Shah P. Efficacy and safety
538	of the drugs used to reverse direct oral anticoagulants: a systematic review and meta-
539	analysis. Transfusion. 2017;57(7):1834.
540	24. Chaudhary R, Singh A, Chaudhary R, Bashline M, Houghton DE, Rabinstein A, Adamski
541	J, Amdt R, Ou NN, Rudis MI, et al. Evaluation of direct oral anticoagulant reversal
542	agents in intracranial hemorrhage: a systematic review and meta-analysis. JAMA Netw
543	Open. 2022;5(11):e2240145.
544	25. Singh S, Nautiyal A, Belk KW. Real world outcomes associated with idarucizumab:
545	population-based retrospective cohort study. Am J Cardiovasc Drugs. 2020;20(2):161-
546	168.
547	26. Abraham NS, Barkun AN, Sauer BG, Douketis J, Laine L, Noseworthy PA, Telford JJ,
548	Leontiadis GI. American College of Gastroenterology-Canadian Association of
549	Gastroenterology Clinical Practice Guideline: Management of Anticoagulants and
550	Antiplatelets During Acute Gastrointestinal Bleeding and the Periendoscopic Period. Am
551	J Gastroenterol. 2022;117(4):542-558.
552	27. Kozar RA, Holcomb JB, Xiong W, Nathens AB. Are all deaths recorded equally? The
553	impact of hospice care on risk-adjusted mortality. J Trauma Acute Care Surg.
554	2014;76(3):634-9.
555	28. Sloos PH, Maas MAW, Hollmann MW, Juffermans NP, Kleinveld DJB. The effect of
556	shock duration on trauma-induced coagulopathy in a murine model. Intensive Care Med
557	<i>Exp</i> . 2022;10(1):1.
558	29. Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal—full
559	cohort analysis. N Engl J Med. 2017;377(5):431-441.

560 SUPPLEMENTAL FILES

561 Supplemental files are intended for publication as an online data supplement.

Figure 1. CONSORT diagram for the Comparison of Administered Idarucizumab Study Sample Derivation

